Extended Anticoagulation Therapy With Rivaroxaban for Cancer‐Associated Low‐Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial
Extended Anticoagulation Therapy With Rivaroxaban for Cancer‐Associated Low‐Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial
Nao Muraoka, Tatsuhiro Shibata, Wataru Shioyama, Nagisa Morikawa et al.
Journal
Journal of the American Heart Association
Topics
Venous Thromboembolism Diagnosis and Management
article
Extended Anticoagulation Therapy With Rivaroxaban for Cancer‐Associated Low‐Risk Pulmonary Embolism According to Different Performance Status Scores: Insights From the ONCO PE Randomized Trial
Nao Muraoka, Tatsuhiro Shibata, Wataru Shioyama, Nagisa Morikawa, Yoshihisa Nakagawa, Hiromi Yamamoto, Yugo Yamashita, Y Nishimoto, K Ono, Takeshi Morimoto, Wei Xiong, Takeshi Kimura, the ONCO PE Trial Investigators, Yoshihiro Fukumoto, Ryuki Chatani
article en
Abstract
No abstract available for this paper.
Publication Tag
Journal of the American Heart AssociationVol. 15(6)
Institutions
Kurume University (JP), Shiga University of Medical Science (JP), Kyoto University (JP), XinHua Hospital (CN), Osaka Prefectural Medical Center (JP), Shizuoka Cancer Center (JP), Kurashiki Central Hospital (JP), Municipal Hirakata City Hospital (JP), Hyogo University (JP)